Endo Reiterates US Generics Environment Is ‘Challenging’
Follows Recent Comments By Sandoz And Teva
Endo’s non-injectable Generics revenues plunged by 28% in Q1, in part due to competitive challenges in the US generics sector that management said would continue through 2021.
You may also be interested in...
Endo management turned talk once again to its expectations for Vasostrict competition in the coming months during its year-end earnings call. The US-based firm enjoyed a better end to the year as it capitalized on the opportunity for shortage-hit varenicline.
Endo still sees significant potential in Vasostrict despite the onset of competition. Meanwhile, the firm says it is focusing on “optimizing” its generics business.
Two months after announcing the deal, Strides Pharma Science has closed its acquisition of a US manufacturing site and basket of ANDAs from Endo, doubling the company’s burgeoning US business and providing much-needed cash to the US-based company.